Salute e Benessere

DermRays Celebrates International Women's Day with the Launch of the FusionGlow…

"At DermRays, we believe in empowering women to feel confident and radiant in their own skin," said a spokesperson for the brand. "This International Women's Day, we're thrilled to introduce the FusionGlow and offer exclusive discounts to celebrate the incredible women who inspire us every day. We invite women everywhere to join us this March and take advantage of these exclusive offers to enhance their skincare routines." "At DermRays, we believe in empowering women to…
PR Newswire
01/03/2025

Global surge in serious heart rhythm disorders sparks urgent call to action from…

Heart rhythm disorders, also known as cardiac arrhythmias, occur when the heart's electrical conduction system malfunctions, causing the heart to beat too quickly, slowly, or irregularly. While some heart rhythm disorders are harmless, others can lead to severe complications. Heart rhythm disorders, also known as cardiac arrhythmias, occur when the heart's electrical conduction system malfunctions, causing the heart to beat too quickly, slowly, or irregularly. While some heart rhythm…
PR Newswire
01/03/2025

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; February 28, 2025 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company's managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to...
Nasdaq GlobeNewswire
28/02/2025

Grant of Restricted Stock Units to Management and Employees and Grant of…

Company Announcement COPENHAGEN, Denmark; February 28, 2025 –Genmab A/S(Nasdaq: GMAB) announced today that the Board decided to grant 614,676 restricted stock units to members of management and employees of the Company as well as the Company's subsidiaries and 517,191 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK...
Nasdaq GlobeNewswire
28/02/2025

hellocare.ai to Implement Virtual Care Solution at AdventHealth to Enhance…

"We are always seeking new ways to ensure every patient feels even more informed and supported during their care experience," said Duncan Grodack, executive vice president and chief information officer for AdventHealth. "With the introduction of this technology, we're giving patients greater access to their care team, providing additional support for our bedside caregivers and ensuring that loved ones can stay connected." "We are always seeking new ways to ensure every…
PR Newswire
28/02/2025

BNCT Market Booms with 38.7% CAGR - A Game-Changer in Cancer Treatment |…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-11S15473/Global_Boron_Neutron_Capture_Therapy_BNCT_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-11S15473/Global_Boron_Neutron_Capture_Therapy_BNCT_Market Major Factors Driving the Growth of Boron Neutron Capture Therapy (BNCT) Market: The Boron Neutron Capture Therapy (BNCT) market is evolving rapidly, driven by technological innovations, increased clinical...
PR Newswire
28/02/2025

Enzymatica AB: Invitation to Press Briefing - 5 March 2025

Read the press release published on 28 February here:https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/ Read the press release published on 28 February here: https://www.enzymatica.com/media/press-releases/2025/new-independent-studies-show-that-coldzyme-addresses-the-root-cause-of-respiratory-infections-reducing-sick-days-and-symptoms/ Link to the published...
PR Newswire
28/02/2025

Valneva Receives EMA's Positive CHMP Opinion for Adolescent Label Extension for…

If granted, IXCHIQ ®will become the first vaccine against the chikungunya virus (CHIKV) available in the EU for adolescents 12 years of age and older Saint Herblain (France), February 28, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending authorization of a label extension for IXCHIQ ®,...
Nasdaq GlobeNewswire
28/02/2025

Disposable Gloves Market Size to Reach a Value of US$17.66 Billion by 2031, The…

For More Information and To Stay Updated on The Latest Developments in The Disposable Gloves Market, Download The Sample Pages: https://www.theinsightpartners.com/sample/TIPRE00005313/ For More Information and To Stay Updated on The Latest Developments in The Disposable Gloves Market, Download The Sample Pages: https://www.theinsightpartners.com/sample/TIPRE00005313/ Overview of Report Findings Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: ...
PR Newswire
28/02/2025

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya…

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025.COPENHAGEN, Denmark, February 28, 2025– Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA ®for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.The virus-like particle (VLP)...
Nasdaq GlobeNewswire
28/02/2025

Cosmetic Polymer Ingredients Market Size to Become Worth US$ 11.59 billion by…

Overview of Report Findings Overview of Report Findings Need A Diverse Region or Sector? Customize Research to Suit Your Requirement: https://www.theinsightpartners.com/inquiry/TIPRE00039365/ Market Segmentation Competitive Strategy and Development Global Headlines on Cosmetic Polymer Ingredients Purchase Premium Copy of Global Cosmetic Polymer Ingredients Market Size and Growth Report (2023-2031) at: https://www.theinsightpartners.com/buy/TIPRE00039365/ ...
PR Newswire
28/02/2025

New independent studies show that ColdZyme addresses the root cause of…

The research team at Kent enrolled 164 active athletes who were randomized to use either ColdZyme or a placebo spray in their throat at the first signs of upper respiratory infection symptoms. Participants also submitted throat swabs for researchers to analyze the presence of viruses during symptom periods. The final results are based on 154 participants, as 10 of the 164 enrolled athletes were lost in follow-up. The results showed that athletes using the active product had significantly lower…
PR Newswire
28/02/2025

Orion Corporation: Managers' transactions – Outi Vaarala

ORION CORPORATIONMANAGERS' TRANSACTIONS28 FEBRUARY 2025 at 17.45 EET Orion Corporation: Managers' transactions – Outi Vaarala Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the notification...
Nasdaq GlobeNewswire
28/02/2025

HIV Diagnosis Market to Hit USD 5.31 Billion by 2030 with 10.3% CAGR |…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66008285 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66008285 Browse in-depth TOC on "HIV Diagnosis Market" 332 - Tables 50 - Figures 273 - Pages Based on product type, the HIV diagnostics market is divided into consumables, instruments and software& services. In 2024, the consumables segment accounted for the largest share of the HIV diagnostics...
PR Newswire
28/02/2025

pH Buffer Solution Market Size to Become a Worth US$ 2.26 Billion by 2031 Driven…

The rising demand from the personal care industry is expected to propel the market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The rising demand from the personal care industry is expected to propel the market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. For More Information and To Stay Updated on The Latest Developments in The pH Buffer...
PR Newswire
28/02/2025

Medical Gas and Equipment Market is expected to generate a revenue of USD 5.01…

The Medical Gas and Equipment Market is witnessing significant expansion, driven by increasing demand for respiratory therapies, advancements in healthcare infrastructure, and the growing adoption of home healthcare solutions. The report delves into the critical factors shaping this market. The Medical Gas and Equipment Market is witnessing significant expansion, driven by increasing demand for respiratory therapies, advancements in healthcare infrastructure, and the growing adoption of home...
PR Newswire
28/02/2025

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES…

Brujic said, "LACRIFILL Canalicular Gel has proven to be something special in my practice. This case series covers three patients amongst the many patients I have treated that showed significant corneal improvement and comfort when treated with LACRIFILL Canalicular Gel. I have also been able to increase the number of occlusions I perform in my practice with LACRIFILL Canalicular Gel." Brujic said, "LACRIFILL Canalicular Gel has proven to be something special in my practice. This…
PR Newswire
28/02/2025

Orion Corporation: Managers' transactions – Niclas Lindstedt

ORION CORPORATIONMANAGERS' TRANSACTIONS28 FEBRUARY 2025 at 17.00 EET Orion Corporation: Managers' transactions – Niclas Lindstedt Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.Orion Oyj - Managers' Transactions ____________________________________________ Person subject to the...
Nasdaq GlobeNewswire
28/02/2025

Novartis data presentations at AAAAI and AAD underscore commitment to advancing…

Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx ®(secukinumab) treatment in HS to be presentedNew analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presentedRegulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025Basel, February 28, 2025– Novartis...
Nasdaq GlobeNewswire
28/02/2025

Ultimovacs ASA: Approval and publication of prospectus

Oslo, 28 February, 2025: Reference is made to the stock exchange announcement by Ultimovacs ASA ("Ultimovacs" or the "Company") on 17 December 2024 regarding the agreement to combine its business with Zelluna Immunotherapy AS (the "Business Combination") and the fully committed private placement (the "Private Placement"). The Company has prepared a prospectus in connection with the listing on Euronext Oslo Børs of (i) the 147,991,521 shares in the Company…
Nasdaq GlobeNewswire
28/02/2025

AIM announces Paul Goepfert, MD, as the principal investigator for the planned…

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham (“UAB”), has agreed to act as the Principal Investigator for the company's planned clinical study in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. Ampligen would serve as a...
Nasdaq GlobeNewswire
28/02/2025

CHMP recommends EU approval of Roche's Columvi combination for people with…

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2DLBCL—an aggressive disease with a high risk of progression—remains an area of high unmet need, especially for treatments that can be initiated soon after the cancer returns If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapseBasel, 28 February 2025 -...
Nasdaq GlobeNewswire
28/02/2025

The Committee for Medicinal Products for Human Use (CHMP) reaffirms positive…

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates). Aβ protofibrils are a key toxic form of Aβ that continue to accumulate in the brain and cause neuronal injury after plaque reduction. Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ…
PR Newswire
28/02/2025

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the…

If approved, Fabhalta ®will be the only medicine indicated to selectively target the underlying cause of C3G 1, an ultra-rare, progressive kidney disease with no currently approved treatments 2-5 Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction 6 ; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed 6-8 ​C3G is typically diagnosed in young adults 2-5 ;...
Nasdaq GlobeNewswire
28/02/2025
Altri  Comunicati